# Bundibugyo Ebola virus

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/bundibugyo-ebola-virus
Canonical HTML page: https://gethealthbrief.com/entity/bundibugyo-ebola-virus

## Timeline

- **2026-07-14**: First-in-Human Trial Begins — A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
- **2026-05-18**: WHO Declares Public Health Emergency — The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.

## Recent coverage (1 stories)

### First Human Trial of Bundibugyo Ebola Vaccine Begins as Death Toll Tops 700
2026-07-20 14:14:43 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Full story: https://gethealthbrief.com/story/first-human-trial-bundibugyo-ebola-vaccine-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.